NAVB vs. IDXX, LNTH, NEOG, CLDX, QDEL, MYGN, NTLA, ACHV, TKNO, and VNRX
Should you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include IDEXX Laboratories (IDXX), Lantheus (LNTH), Neogen (NEOG), Celldex Therapeutics (CLDX), QuidelOrtho (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Achieve Life Sciences (ACHV), Alpha Teknova (TKNO), and VolitionRx (VNRX). These companies are all part of the "diagnostic substances" industry.
IDEXX Laboratories (NASDAQ:IDXX) and Navidea Biopharmaceuticals (NYSE:NAVB) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.
IDEXX Laboratories received 529 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 72.47% of users gave IDEXX Laboratories an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote.
87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 2.1% of IDEXX Laboratories shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
IDEXX Laboratories has a net margin of 23.26% compared to IDEXX Laboratories' net margin of 0.00%. Navidea Biopharmaceuticals' return on equity of 63.66% beat IDEXX Laboratories' return on equity.
IDEXX Laboratories has higher revenue and earnings than Navidea Biopharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
In the previous week, IDEXX Laboratories had 20 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 20 mentions for IDEXX Laboratories and 0 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.64 beat IDEXX Laboratories' score of 0.00 indicating that IDEXX Laboratories is being referred to more favorably in the media.
IDEXX Laboratories has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.
IDEXX Laboratories presently has a consensus price target of $585.89, indicating a potential upside of 23.76%. Given Navidea Biopharmaceuticals' higher possible upside, research analysts plainly believe IDEXX Laboratories is more favorable than Navidea Biopharmaceuticals.
Summary
IDEXX Laboratories beats Navidea Biopharmaceuticals on 15 of the 17 factors compared between the two stocks.
Get Navidea Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Navidea Biopharmaceuticals Competitors List
Related Companies and Tools
Free NAVB Stock Alerts